Abstract

Second most common cancer in man is prostatic carcinoma  and is very important cause of morbidity and approximately 6.7% mortality, worldwide^1,2.Incidental prostate carcinoma is defined as subclinical and asymptomatic tumor that is neither palpable nor visible by imaging. They are diagnosed only at the time of  transurethral resection of the prostate(TURP) for benign prostatic hyperplasia(BPH)².TURP targets mostly the transitional zone of the prostate, but the Prostatic carcinomaisolated in transitional zone is uncommon, and a few tumour may not cause a increase in PSA, especially in case of low volume^3,4.  
In various studies in the literature, the prevalence of IPC is reported to vary between 1.4 to 16.7%⁵. Although the incidence of IPC in TURP  specimens has been markedly decreased due to the widespread use of serum PSA screening.
Along with this shift in incidental prostate cancer distribution with introduction of PSA, newer techniques, such as laser vaporization, are being performed⁶. But these newer technologies do not  provide tissue for pathological examination leading to potential for missing the detection of incidental prostatic carcinoma.
Most IPCs are considered clinically insignificant, but in recent few studies , It has been suggested that in some cases the clinical course becomes more unfavourable⁸.Some IPCs have been shown to be clinically significant, specifically tumours with higher Gleason score and Stage⁶. The hypothesis of this study is a more comprehensive clinicopathological assessment and  correlation of IPCs with various serological and clinical parameter for the better management of patients.